The aim of the study was evaluation of remdesivir, an RNA polymerase inhibitor, for effectiveness in adults with COVID-19.
52 randomized clinical trials were screened and 4 studies were included in analysis, with total of 7324 patients. Significantly higher rates of clinical improvement (OR=1.52 (95% CI 1.24 to 1.87), p<0.0001, low quality) and faster time to clinical improvement (HR=1.28 (95% CI 1.12 to 1.46), p=0.0002, very low quality) was observed with remdesivir versus control group. Significant decrease was found in the risk of serious adverse events (RR=0.75 (95% CI 0.62 to 0.90), p=0.0003, low quality); however, no difference was found in the risk of respiratory failure (RR=0.85 (95% CI 0.41 to 1.77), p=0.67, very low quality evidence) with remdesivir. No mortality benefit was observed with remdesivir versus control group (OR=0.92 (95% CI 0.79 to 1.07), p=0.30, moderate quality evidence).
Surjit Singh, Daisy Khera, Ankita Chugh, Pushpinder Singh Khera, and Vinay Kumar Chugh: Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. BMJ Open. 2021; 11(6): e048416. doi: 10.1136/bmjopen-2020-048416